Sumanta K. Pal: Misalignment Between Clinical Trial Access and Disease Burden in US Bladder Cancer
Sumanta K. Pal/ X

Sumanta K. Pal: Misalignment Between Clinical Trial Access and Disease Burden in US Bladder Cancer

Sumanta K. Pal, Vice Chair of Academic Affairs and Professor at City of Hope, shared on X:

“Tremendous work from a team led by Koral Shah, Salvador Jaime-Casas and Ruchi Agarwal, co-first authors on this piece in JAMA Network Open highlighting the regional variations in bladder cancer trials in the US.

Their detailed analysis of regional variations in study availability points to a misalignment between trial access and disease burden. Tagging IBCG, Bladder Cancer Advocacy Network and other groups fighting for access to clinical trials for our patients.”

Title: Regional Variation in Bladder Cancer Clinical Trial Availability in the US

Authors: Koral U. Shah, Salvador Jaime-Casas, Ruchi Agarwal, George Zhang, Xiaochen Li, Vitor Abreu de Goes, Daniela V. Castro, Benjamin Mercier, Ruth Simon, Samuel Dickter, Lily M. Lau, Jaya Goud, Akasha Dukkipati, Jadon Fann, Lauren Lau, Joshua Lee, Kyra Shah, Ethan Swarat, Miguel Zugman, Nazli Dizman, Ali Moradi, Regina Barragan-Carrillo, Abhishek Tripathi, Charles B. Nguyen, Alex Chehrazi-Raffle, Sumanta K. Pal

Read the full article.

You may also find this interesting:

Tommy John and Bladder Cancer: The Inspiring Story of a Baseball Legend Who Changed Sports Medicine

Sumanta K. Pal: Misalignment Between Clinical Trial Access and Disease Burden in US Bladder Cancer